StockCIK 1800315

Damora Therapeutics, Inc. (DMRA): Insider Trades and Fund Holdings

In the past 12 months, Damora Therapeutics, Inc. insiders reported 1 open-market purchase worth $253K and 0 sales worth $0.

1Insider buys, 12 months

$253KBought by insiders, 12 months

$0Sold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 28, 2026.

Recent DMRA insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Sep 28	Sep 25	Jennifer JarrettCEO	CEO	▲ BUY	12,500	20.23	$253K	+2.5%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
Jennifer Jarrett	CEO	1	$253K	0	$0	Sep 28, 2026

Tracked funds that report DMRA

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Viking Global Investors	Q2 2026	2,311,082	$60.1M	0.17%	No change

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →